Rules/misleading presentation/US-MIS-013

No misleading pooled statistics in prescription drug advertising

DisputedblockerBinding lawRaised as a question — a person decides

Rule

In advertising for a prescription drug, statistics on numbers of patients, or counts of favorable results or side effects, derived from pooling data from various insignificant or dissimilar studies must not be presented in a way that suggests such statistics are valid when they are not, or that they derive from large or significant studies supporting favorable conclusions when they do not. This provision applies only to advertisements for prescription drugs, not to OTC drug advertising or to non-advertising promotional labeling.

Check

Confirm the piece is an advertisement for a prescription drug (not an OTC drug ad and not promotional labeling such as a package insert or detail piece). Where such an advertisement presents a pooled statistic (patient counts, counts of favorable results, or side-effect counts), identify the underlying studies and assess whether they are dissimilar or individually insignificant, and whether the presentation suggests the pooled figure is statistically valid, or that it comes from large or significant studies supporting favorable conclusions, when it does not.

Escalate when

Validity of the pooling methodology or its presentation is a matter of statistical judgment, or there is ambiguity about whether the piece qualifies as an "advertisement" versus promotional labeling under the regulation.

Where this comes from

21 CFR 202.1(e)(6)(xiv). The highlighted words are quoted exactly; a script confirms they appear in the source before the rule can be published.

… any of the components rather than limiting the indications for use to patients for whom concomitant therapy as provided by the fixed combination drug is indicated, unless such condition is included in the uses permitted under paragraph (e)(4) of this section. (xiii) Uses a study on normal individuals without disclosing that the subjects were normal, unless the drug is intended for use on normal individuals. (xiv) Uses “statistics” on numbers of patients, or counts of favorable results or side effects, derived from pooling data from various insignificant or dissimilar studies in a way that suggests either that such “statistics” are valid if they are not or that they are derived from large or significant studies supporting favorable conclusions when such is not the case. (xv) Uses erroneously a statistical finding of “no significant difference” to claim clinical equivalence or to deny or conceal the potential existence of a real clinical difference. (xvi) Uses statements or representations that a drug differs from or does not contain a named drug or category of drugs, or that it has a greater potency per unit of weight, in a way that suggests falsely or misleadingly or without sub…

Open the original at these words on ecfr.gov ↗Read our full copy →

Document: 21 CFR 202.1
Version: 2026-09-16 — the link above is pinned to this date, so it shows the text as it stood then
Retrieved: 2026-09-21 from www.ecfr.gov
Fingerprint: a542640a872b3f2702d549e8…

Applies when

Naturepromotional

Productdrug

Rx statusprescription

Communication typeadvertisement

How this rule was checked

The verifier and drafter could not agree. Waiting for a human decision — not used in reviews.

Drafted
claude-sonnet-5 · 2026-09-21
Independent verification — revise
claude-opus-5 · 2026-09-21
Reviewer's reasons
- Core support is genuine: the quote is the operative text of 21 CFR 202.1(e)(6)(xiv), located in the affirmative list at (e)(6) ('An advertisement for a prescription drug is false, lacking in fair balance, or otherwise misleading ... if it:'), not in an example, definition, or preamble. The rule statement tracks the two disjunctive prongs (suggesting the pooled statistics are valid when they are not; suggesting they derive from large or significant supporting studies when they do not).
- Authority 'binding' is correct — this is a codified FDA regulation, and (e)(6) is stated in mandatory 'is false ... misleading' terms, not 'may be'. Note the contrast with (e)(7), which is the 'may be false' list; the drafter correctly used an (e)(6) item for a hard obligation.
- Determinism 'judgment' is correct — whether studies are 'insignificant or dissimilar' and whether a presentation 'suggests' invalid validity or large-study provenance all turn on impression and scientific assessment, not literal match.
- Severity 'blocker' is defensible: violation of (e)(6) renders the ad misleading and violative of section 502(n), i.e., misbranding.
- OVERSTATEMENT in the check: 'whether pooling methodology is disclosed' imports an affirmative disclosure requirement that (e)(6)(xiv) does not contain. The provision prohibits a misleading suggestion; it does not mandate disclosure of pooling methodology. Compare (e)(6)(vi) and (e)(6)(xiii), where the regulation expressly frames violations as 'failure to disclose' — (xiv) is deliberately not phrased that way. A reviewer applying this check could flag compliant material solely for absent methodology disclosure.
- Wording defect in the rule statement: 'suggests invalid validity' is garbled and does not convey the regulatory standard ('suggests that such statistics are valid if they are not').
- applies_when scope: (e)(6) by its terms governs advertisements for prescription drugs. Tagging the rule simply 'promotional' is broader than the cited text and would sweep in materials (e.g., non-prescription products) the provision does not reach.
- Locator is correct: the quoted sentence is item (xiv) under (e)(6) in the supplied text.
Revised by the drafter
claude-sonnet-5 · 2026-09-21
Independent verification — revise
claude-opus-5 · 2026-09-21
Reviewer's reasons
- Supported: the quote is operative regulatory text from the enumerated list at 21 CFR 202.1(e)(6), introduced by 'An advertisement for a prescription drug is false, lacking in fair balance, or otherwise misleading, or otherwise violative of section 502(n) of the act, among other reasons, if it:'. It is not an example, definition, or preamble, and item (xiv) is a per se listing rather than a permissive one.
- Faithful transposition: the rule statement preserves both disjunctive limbs of (xiv) (suggesting the statistics are valid when they are not; suggesting they derive from large or significant studies supporting favorable conclusions when they do not) and the predicate that the pooled data come from 'insignificant or dissimilar studies'. Nothing is added.
- Correctly distinguished from paragraph (e)(7)(ii), (iii) and (v), which address statistical significance, retrospective analysis and unsound statistical methodology but are framed as 'may be false, lacking in fair balance, or otherwise misleading'. Drafting from (e)(6) rather than (e)(7) is what licenses the mandatory phrasing and blocker severity.
- determinism 'judgment' is right: the test turns on whether the presentation 'suggests' validity or scale, and on whether underlying studies are 'insignificant or dissimilar' — none of which is settled by presence/absence or a literal match.
- authority 'binding' is right: this is codified regulation (21 CFR), not guidance.
- severity 'blocker' is defensible: material meeting this description is deemed false/lacking in fair balance/otherwise misleading and violative of section 502(n), i.e. renders the drug misbranded.
- atomic: the two suggestion-limbs are alternative triggers for a single prohibition on a single presentation, not independently checkable obligations.
- Locator 21 CFR 202.1(e)(6)(xiv) and the quoted text match the source exactly.
- Overstated on scope only: the governing sentence limits this paragraph to 'an advertisement for a prescription drug', but applies_when is {promotional, drug} and the rule statement carries no qualifier, so as written it reaches OTC drug materials and non-advertising promotional labeling that this provision does not govern.
- The check is actionable — it directs the reviewer to identify the underlying studies, assess dissimilarity/insignificance, and evaluate the impression created — and the escalate-when condition correctly routes statistical methodology questions to a specialist.
Revised by the drafter
claude-sonnet-5 · 2026-09-21
Independent verification — revise
claude-opus-5 · 2026-09-21
Reviewer's reasons
- Quote matches 21 CFR 202.1(e)(6)(xiv) verbatim and the locator is correct.
- The governing stem of (e)(6) states that an advertisement for a prescription drug 'is false, lacking in fair balance, or otherwise misleading, or otherwise violative of section 502(n)' if it does any of the listed things, so stating (xiv) as a mandatory prohibition is faithful rather than overstated; this is the per-se list, distinct from the 'may be false' list in (e)(7).
- Blocker severity is defensible: a violation of (e)(6) is a per-se finding of misleading advertising and misbranding under section 502(n).
- 'judgment' is correct: the trigger depends on whether the presentation 'suggests' validity or derivation from large/significant studies, and on whether underlying studies are 'insignificant or dissimilar' — none of which is settled by presence/absence or literal match.
- 'binding' is correct; the source is a codified regulation.
- Atomic: the two disjunctive suggestions (validity; derivation from large/significant studies) are alternative triggers of a single prohibition assessed in one review step, not independently checkable requirements.
- applies_when (promotional, drug, prescription, advertisement) is directly justified by the stem's 'An advertisement for a prescription drug'.
- Not supported: the rule's second sentence and the first Check step assert an affirmative carve-out — that the provision does not apply to OTC advertising or to 'non-advertising promotional labeling such as a package insert or detail piece'. The provided source contains no definition of 'advertisement', no advertising/labeling boundary, and no language excluding promotional labeling from this standard. As drafted this gives a reviewer an unsupported clearance rationale for misleading pooled statistics appearing in labeling-type pieces.
- Minor (not required): the closing proviso to (e)(6) in the source permits FDA to waive 'any provision of this paragraph' for a specified advertisement upon petition; the absolute 'must not' omits this, which is acceptable for review purposes but slightly understates the regulation's structure.